UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Trials of antivirals in the treatment of multiple sclerosis

Acta neurologica Scandinavica, 2017-11, Vol.136 (S201), p.45-48

Lycke, J.

2017

Volltextzugriff (PDF)

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients

Annals of neurology, 2020-05, Vol.87 (5), p.688-699

2020

Volltextzugriff (PDF)

Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis

Journal of neurology, 2011-05, Vol.258 (5), p.882-888

2011

Volltextzugriff (PDF)

High nationwide prevalence of multiple sclerosis in Sweden

Multiple sclerosis, 2011-08, Vol.17 (8), p.901-908

2011

Volltextzugriff (PDF)

Longitudinal changes in resting state fMRI brain self-similarity of asymptomatic high school American football athletes

Scientific reports, 2024-01, Vol.14 (1), p.1747-1747, Article 1747

2024

Volltextzugriff (PDF)

Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis

European journal of neurology, 2019-08, Vol.26 (8), p.1060-1067

2019

Volltextzugriff (PDF)

Serum neurofilament light for detecting disease activity in individual patients in multiple sclerosis: A 48-week prospective single-center study

Multiple sclerosis, 2024-05, Vol.30 (6), p.664-673

2024

Volltextzugriff (PDF)

Neurofilament light protein levels in cerebrospinal fluid predict long‐term disability of Guillain‐Barré syndrome: A pilot study

Acta neurologica Scandinavica, 2018-08, Vol.138 (2), p.143-150

2018

Volltextzugriff (PDF)

Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS

Neurology, 2003-12, Vol.61 (12), p.1720-1725

2003

Volltextzugriff (PDF)

A nationwide survey of the influence of month of birth on the risk of developing multiple sclerosis in Sweden and Iceland

Journal of neurology, 2018-01, Vol.265 (1), p.108-114

2018

Volltextzugriff (PDF)

Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society

Acta neurologica Scandinavica, 2017-01, Vol.135 (1), p.17-24

2017

Volltextzugriff (PDF)

Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis

Acta neurologica Scandinavica, 2013-12, Vol.128 (6), p.e33-e36

2013

Volltextzugriff (PDF)

Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis

Journal of neurology, neurosurgery and psychiatry, 1998-03, Vol.64 (3), p.402-404

1998

Volltextzugriff (PDF)

Clinical effectiveness and safety of dimethyl fumarate for patients treated at least 6 years in the swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 5" (IMSE 5)

MULTIPLE SCLEROSIS JOURNAL, 2022, Vol.28 (Suppl. 3), p.858

2022

Volltextzugriff (PDF)

Clinical effectiveness and safety of cladribine tablets for patients treated at least 12 months in the Swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 10" (IMSE 10)

MULTIPLE SCLEROSIS JOURNAL, 2022, Vol.28 (Suppl. 3), p.638

2022

Volltextzugriff (PDF)

Improved clinical outcomes in patients treated with natalizumab for at least 11 years - real-world data from a swedish national post-marketing surveillance study (IMSE 1)

MULTIPLE SCLEROSIS JOURNAL, 2022, Vol.28 (Suppl. 3), p.352

2022

Volltextzugriff (PDF)

CLADCOMS - CLADribine tablets long-term Control Of MS - a post-marketing investigator driven study

MULTIPLE SCLEROSIS JOURNAL, 2022, Vol.28 (Suppl. 3), p.847

2022

Volltextzugriff (PDF)

Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: randomized RECYCLINE study

European journal of neurology, 2016-05, Vol.23 (5), p.861-870

2016

Volltextzugriff (PDF)

Imaging of small animal peripheral artery disease models: recent advancements and translational potential

International journal of molecular sciences, 2015-05, Vol.16 (5), p.11131-11177

2015

Volltextzugriff (PDF)

Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs

Multiple sclerosis, 2013-05, Vol.19 (6), p.765-774

2013

Volltextzugriff (PDF)

Minocycline added to subcutaneous interferon [beta]-1a in multiple sclerosis: randomized RECYCLINE study

European journal of neurology, 2016-05, Vol.23 (5), p.861

2016

Volltextzugriff (PDF)

Trajectories of processing speed, disability, and their connections, over the years following disease modulatory treatment initiation among relapsing-remitting multiple sclerosis patients

MULTIPLE SCLEROSIS JOURNAL, 2021, Vol.27 (Suppl. 2), p.677

2021

Volltextzugriff (PDF)

Effectiveness of initial MS treatments in the COMBAT-MS trial: injectables, dimethyl fumarate, natalizumab and rituximab

MULTIPLE SCLEROSIS JOURNAL, 2021, Vol.27 (Suppl. 2), p.21

2021

Volltextzugriff (PDF)

Rituximab treatment did not aggravate ongoing progressive multifocal leukoencephalopathy in a patient with multiple sclerosis

Journal of the neurological sciences, 2015, Vol.353 (1), p.155-157

2015

Volltextzugriff (PDF)

NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS

Multiple sclerosis and related disorders, 2020-11, Vol.46, p.102463-102463, Article 102463

2020

Volltextzugriff (PDF)

1 – 25 von 400

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(369)
Mit Volltextzugriff
(340)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Trials of antivirals in the treatment of multiple sclerosis

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients

Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis

High nationwide prevalence of multiple sclerosis in Sweden

Longitudinal changes in resting state fMRI brain self-similarity of asymptomatic high school American football athletes

Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis

Serum neurofilament light for detecting disease activity in individual patients in multiple sclerosis: A 48-week prospective single-center study

Neurofilament light protein levels in cerebrospinal fluid predict long‐term disability of Guillain‐Barré syndrome: A pilot study

Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS

A nationwide survey of the influence of month of birth on the risk of developing multiple sclerosis in Sweden and Iceland

Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society

Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis

Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis

Clinical effectiveness and safety of dimethyl fumarate for patients treated at least 6 years in the swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 5" (IMSE 5)

Clinical effectiveness and safety of cladribine tablets for patients treated at least 12 months in the Swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 10" (IMSE 10)

Improved clinical outcomes in patients treated with natalizumab for at least 11 years - real-world data from a swedish national post-marketing surveillance study (IMSE 1)

CLADCOMS - CLADribine tablets long-term Control Of MS - a post-marketing investigator driven study

Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: randomized RECYCLINE study

Imaging of small animal peripheral artery disease models: recent advancements and translational potential

Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs

Minocycline added to subcutaneous interferon [beta]-1a in multiple sclerosis: randomized RECYCLINE study

Trajectories of processing speed, disability, and their connections, over the years following disease modulatory treatment initiation among relapsing-remitting multiple sclerosis patients

Effectiveness of initial MS treatments in the COMBAT-MS trial: injectables, dimethyl fumarate, natalizumab and rituximab

Rituximab treatment did not aggravate ongoing progressive multifocal leukoencephalopathy in a patient with multiple sclerosis

NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS

Suchergebnisse filtern